Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,772 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Clear all
Completed Phase 3 Interventional

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions
Cariprazine Flexible Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD

NCT01438372
View directory record Official record
Conditions
Iron Deficiency Anemia, Inflammatory Bowel Disease
Interventions
Intravenous iron sucrose, Oral ferrous sulfate
Drug
Lead sponsor
Wayne State University
Other
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

NCT06941272
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Patritumab Deruxtecan
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Month to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

NCT04671901
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma
Interventions
Romiplostim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 4 Interventional

Home Care Management of Pediatric Pain

NCT00251628
View directory record Official record
Conditions
Tonsillectomy
Interventions
Standard Care, ATC Dosing, Structured Pain Management Program, As needed dosing
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 15 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Madera, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Food Genetics Behavior Study

NCT05783765
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Heightened Drive to Eat
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
5 Years to 7 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

NCT04516967
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management

NCT05630729
View directory record Official record
Conditions
Chronic Kidney Diseases, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage V, Chronic Kidney Disease Stage 5, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage I, Chronic Kidney Disease, Stage IV (Severe), Pediatric Kidney Disease
Interventions
My Kidney Guru
Other
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
13 Years to 25 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 21, 2026, 2:42 AM EDT
Not listed Phase 1 Interventional

Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors

NCT00003073
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
liposomal cytarabine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

NCT02340169
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Topicort® (desoximetasone) Topical Spray, 0.25%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Enrolling by invitation Not applicable Interventional

Parent Tube Weaning Interviews

NCT07054983
View directory record Official record
Conditions
Feeding Difficulties, Remote Patient Monitoring, Pediatric Feeding Disorders
Interventions
Qualitative Research Interview
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Phase 3 Interventional

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

NCT05768854
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Bisphosphonate, Setrusumab
Drug · Biological
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
2 Years to 6 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population

NCT03482154
View directory record Official record
Conditions
Stem Cell Transplant Complications, Hyperglycemia, Hypoglycemia
Interventions
Hematopoietic Stem Cell Transplant
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 30 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

NCT00186953
View directory record Official record
Conditions
Abdominal Neoplasms, Pelvic Neoplasms
Interventions
Optison
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 21, 2026, 2:42 AM EDT
Recruiting Phase 2 Interventional

Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety

NCT06595953
View directory record Official record
Conditions
Psychiatric Disorders, Anxiety Disorders
Interventions
Gaze-Contingent Music Reward Therapy
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed No phase listed Observational

Immune Development in Pediatric Transplantation (IMPACT)

NCT00951353
View directory record Official record
Conditions
Chronic Kidney Failure, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

NCT04786730
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Little Rock, Arkansas • Decatur, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Triferic Pediatric Pharmacokinetic Protocol

NCT02595437
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

First Heroes: Engaging Fathers in the First 1000 Days

NCT04477577
View directory record Official record
Conditions
Obesity, Childhood, Overweight and Obesity, Social Determinants of Health, Physical Activity, Feeding Behavior, Sleep, Diet Habit
Interventions
New Parent Intervention, Safety Control
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The STOP-HPV Trial 1: Communication Intervention

NCT03599557
View directory record Official record
Conditions
Immunization, Vaccination
Interventions
STOP-HPV communication intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Itasca, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01231919
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Aggressive NK-cell Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Noncutaneous Extranodal Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 21, 2026, 2:42 AM EDT
Not yet recruiting Phase 2 Interventional

Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia

NCT07554131
View directory record Official record
Conditions
Refractory Amblyopia
Interventions
Echothiophate Iodide 0.125% Ophthalmic Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Active, not recruiting Not applicable Interventional

A Randomized Control Trial of Motor-based Intervention for CAS

NCT04642053
View directory record Official record
Conditions
Childhood Apraxia of Speech
Interventions
Dynamic Temporal and Tactile Cuing
Behavioral
Lead sponsor
New York University
Other
Eligibility
29 Months to 95 Months
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Oral Dexamethasone Doses in Asthma Exacerbation

NCT00942201
View directory record Official record
Conditions
Asthma, Reactive Airway Disease
Interventions
Dexamethasone
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
2 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 21, 2026, 2:42 AM EDT